Pacira Secures Unanimous Proxy Advisor Support, Highlights Strong Q1 Amidst Proxy Battle
Summary
Pacira BioSciences has received unanimous support from leading proxy advisory firms (ISS, Glass Lewis, Egan-Jones) for its board nominees, a major boost in its proxy battle against DOMA Perpetual Capital Management. The company also highlighted strong Q1 2026 revenue growth and pipeline advancements.
Key Events
-
Unanimous Proxy Advisor Support
ISS, Glass Lewis, and Egan-Jones all recommend stockholders vote "FOR" Pacira's director nominees and "AGAINST" DOMA Perpetual's nominees.
-
Strong Q1 2026 Revenue Growth
Reported EXPAREL revenue up 5%, ZILRETTA up 15%, and iovera° up 21% year-over-year in Q1 2026.
-
Annual Meeting Reminder
Reminds stockholders to vote the BLUE proxy card for the company's nominees ahead of the Annual Meeting on June 9, 2026.
-
Pipeline Progress
Entering a data-rich period with key 2026 readouts expected from Phase 2 study of PCRX-201 and registrational studies for ZILRETTA and iovera°.
Analysis
This filing provides a significant update in the ongoing proxy contest with activist investor DOMA Perpetual Capital Management. The unanimous recommendation from ISS, Glass Lewis, and Egan-Jones for Pacira's nominees is a strong endorsement of the current board and strategy, significantly bolstering the company's position ahead of the June 9th Annual Meeting. Additionally, the filing highlights specific positive Q1 2026 revenue growth figures and pipeline progress, reinforcing the company's narrative of strong performance.
At the time of this filing, PCRX was trading at $22.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $891.7M. The 52-week trading range was $18.80 to $27.64. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.